Alkermes (ALKS) Gross Profit Growth (1y) (2011 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Gross Profit Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.50 Bn | 624.74 Bn | 17.26 Bn | 7.10% |
| 2 | AbbVie | 443.58 Bn | 437.01 Bn | 12.70 Bn | 14.64% |
| 3 | Merck | 365.15 Bn | 358.01 Bn | 12.21 Bn | -0.30% |
| 4 | Novartis Ag | 266.63 Bn | 258.94 Bn | 11.24 Bn | -2.37% |
| 5 | Pfizer | 158.52 Bn | 146.82 Bn | 10.94 Bn | 0.62% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 23.11% |
| 7 | Revolution Medicines | 43.95 Bn | 43.95 Bn | - | - |
| 8 | Incyte | 25.37 Bn | 20.83 Bn | 1.57 Bn | 38.03% |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | -3.83% |
| 10 | Alkermes | 7.57 Bn | 6.92 Bn | 397.90 Mn | 16.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.62% |
| Mar 31, 2026 | 28.77% |
| Dec 31, 2025 | -8.03% |
| Sep 30, 2025 | 8.74% |
| Jun 30, 2025 | 1.05% |
| Mar 31, 2025 | -11.80% |
| Dec 31, 2024 | 19.69% |
| Sep 30, 2024 | -1.38% |
| Jun 30, 2024 | -39.07% |
| Mar 31, 2024 | 27.15% |
| Dec 31, 2023 | 22.57% |
| Sep 30, 2023 | 58.35% |
| Jun 30, 2023 | 154.36% |
| Mar 31, 2023 | 2.71% |
| Dec 31, 2022 | -7.42% |
| Sep 30, 2022 | -17.52% |
| Jun 30, 2022 | -13.06% |
| Mar 31, 2022 | 6.17% |
| Dec 31, 2021 | 14.25% |
| Sep 30, 2021 | 10.23% |